Mikael Dolsten
CIK 1437590 · President R&D · last filed 2026-07-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$9.16M
Companies
7
Total Filings
121
Lifetime Open-Market Net
-$31.70M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RCKT | Director | 67,082 | $3.14 | $210.6K | $0 | 1 | 2026-07-06 |
| A | Director | 5,548 | $140.54 | $779.8K | -$606.2K | 8 | 2026-06-02 |
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | Director | 0 | $41.03 | $0 | $0 | 2 | 2026-05-14 |
| RCKTW | Director | 44,220 | $0.00 | $146 | $0 | 3 | 2025-07-18 |
| PFE | President R&D | 323,710 | $25.25 | $8.17M | -$31.09M | 93 | 2024-09-16 |
| KPTI | Director | — | $7.09 | — | $0 | 8 | 2021-05-21 |
| WYETH (WYE) Delisted | Sr. VP & Pres., Wyeth Research | — | — | — | $0 | 1 | 2008-06-18 |
Recent Filings · Page 3 of 13
121 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-03-20 | A | Grant (A) | +1,658 | $226.8K | EDGAR |
| 2023-02-28 | PFE | Tax (F) | −37,078 | -$1.55M | EDGAR |
| 2023-02-24 | PFE | Mixed | −32,592 | -$1.38M | EDGAR |
| 2022-11-09 | PFE | Exer (M) | +79,108 | $2.63M | EDGAR |
| 2022-05-12 | PFE | Mixed | −63,902 | -$3.15M | EDGAR |
| 2022-03-21 | A | Grant (A) | +1,785 | $244.2K | EDGAR |
| 2022-03-04 | PFE | Exer (M) | +102,460 | $3.26M | EDGAR |
| 2022-03-01 | PFE | Tax (F) | −29,744 | -$1.42M | EDGAR |
| 2022-02-25 | PFE | Mixed | −29,767 | -$1.40M | EDGAR |
| 2021-12-21 | PFE | Mixed | +71,187 | $2.15M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.